Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials

PURPOSE: To better clarify the efficacy of neoadjuvant bevacizumab plus chemotherapy (BEV + CT) vs chemotherapy (CT) alone in the treatment of HER2-negative nonmetastatic breast cancer. METHODS: PubMed, Embase, Web of Science, and Cochrane Library databases were searched for relevant articles publis...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jinli, Luo, Yulin, Fu, Deyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296181/
https://www.ncbi.nlm.nih.gov/pubmed/30588017
http://dx.doi.org/10.2147/OTT.S186816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296181/
https://www.ncbi.nlm.nih.gov/pubmed/30588017
http://dx.doi.org/10.2147/OTT.S186816

Ejemplares similares